Citigroup Inc Ovid Therapeutics Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 43,952 shares of OVID stock, worth $45,710. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,952

Previous 14,316 207.01%

Holding current value

$45,710

Previous $11,000 363.64%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.75 - $1.3 $22,227 - $38,526	29,636 Added 207.01%	43,952 $51,000
Q2 2024 Aug 12, 2024	BUY	$0.7 - $3.34 $2,004 - $9,565	2,864 Added 25.01%	14,316 $11,000
Q1 2024 May 10, 2024	BUY	$2.72 - $4.04 $3,878 - $5,761	1,426 Added 14.22%	11,452 $34,000
Q4 2023 Feb 09, 2024	BUY	$2.98 - $3.78 $29,791 - $37,788	9,997 Added 34472.41%	10,026 $32,000
Q3 2023 Nov 09, 2023	SELL	$3.23 - $3.97 $57,264 - $70,384	-17,729 Reduced 99.84%	29 $0
Q2 2023 Aug 10, 2023	BUY	$2.53 - $3.89 $44,927 - $69,078	17,758 New	17,758 $58,000
Q4 2022 Feb 09, 2023	BUY	$1.43 - $1.89 $61 - $81	43 Added 3.6%	1,237 $2,000
Q3 2022 Nov 10, 2022	SELL	$1.84 - $2.26 $437 - $537	-238 Reduced 16.62%	1,194 $2,000
Q2 2022 Aug 10, 2022	SELL	$1.69 - $3.31 $403 - $791	-239 Reduced 14.3%	1,432 $3,000
Q1 2022 May 12, 2022	SELL	$2.65 - $3.49 $1,025 - $1,350	-387 Reduced 18.8%	1,671 $5,000
Q4 2021 Feb 10, 2022	SELL	$3.13 - $3.73 $4,685 - $5,583	-1,497 Reduced 42.11%	2,058 $7,000
Q3 2021 Nov 10, 2021	BUY	$3.31 - $4.04 $11,767 - $14,362	3,555 New	3,555 $12,000

Others Institutions Holding OVID

# of Institutions

Shares Held

39M

Call Options Held

37.4K

Put Options Held

500

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $73.2M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account